Johnson & Johnson presented 120‑week follow‑up data for IMAAVY (nipocalimab‑aahu) at the American Academy of Neurology meeting held April 18‑22, 2026. The data come from the Phase 3 Vivacity‑MG3 study in antibody‑positive patients, including both anti‑AChR+ and anti‑MuSK+ adults.
At 96 weeks in the open‑label extension, 32 % of patients achieved sustained minimal symptom expression, and 57 % reduced corticosteroid use to ≤10 mg/day. Total IgG levels fell, supporting the drug’s mechanism of action. The results reinforce IMAAVY’s safety and efficacy profile and support its continued development toward regulatory approval.
Johnson & Johnson is also enrolling participants in the EPIC study, a head‑to‑head comparison of IMAAVY against efgartigimod, underscoring the company’s commitment to advancing FcRn‑blocking therapy for generalized myasthenia gravis. With roughly 100,000 U.S. patients affected by the condition, the data provide a critical step toward addressing an unmet need.
Earlier in the month, Johnson & Johnson reported Q1 2026 earnings, posting adjusted earnings per share of $2.70 versus an estimate of $2.68 and revenue of $24.06 billion versus an estimate of $23.60 billion. The results reflected strong demand in oncology and immunology segments, offset by a decline in sales of the psoriasis drug STELARA after its patent expired. Management raised full‑year 2026 guidance to $100.8 billion in sales and $11.55 in adjusted EPS, citing continued momentum in its core therapeutic areas.
Chairman and CEO Joaquin Duato said, “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game‑changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long‑term value for shareholders.” Chief Financial Officer Joe Wolk added, “Johnson & Johnson delivered a solid quarter while advancing our portfolio and investing in our new launches to accelerate growth over the long term.”
The 120‑week data for IMAAVY, combined with the company’s robust earnings performance and raised guidance, signals confidence in the drug’s development trajectory and the broader portfolio. Investors will view the sustained clinical benefits as a key milestone toward regulatory approval, while the earnings beat and guidance raise reinforce J&J’s ability to generate growth across its diversified business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.